ATE431159T1 - Für rsv f-proteine spezifische, menschliche, monoklonale antikörper mit hoher affinität - Google Patents

Für rsv f-proteine spezifische, menschliche, monoklonale antikörper mit hoher affinität

Info

Publication number
ATE431159T1
ATE431159T1 AT96919365T AT96919365T ATE431159T1 AT E431159 T1 ATE431159 T1 AT E431159T1 AT 96919365 T AT96919365 T AT 96919365T AT 96919365 T AT96919365 T AT 96919365T AT E431159 T1 ATE431159 T1 AT E431159T1
Authority
AT
Austria
Prior art keywords
rsv
proteins
monoclonal antibodies
high affinity
human monoclonal
Prior art date
Application number
AT96919365T
Other languages
English (en)
Inventor
Peter Brams
Soulaima Chamat
Li-Zhen Pan
Edward Walsh
Cheryl Heard
Roland Newman
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE431159T1 publication Critical patent/ATE431159T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT96919365T 1995-06-07 1996-06-06 Für rsv f-proteine spezifische, menschliche, monoklonale antikörper mit hoher affinität ATE431159T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/488,376 US5811524A (en) 1995-06-07 1995-06-07 Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
PCT/US1996/010070 WO1996040252A1 (en) 1995-06-07 1996-06-06 High affinity human monoclonal antibodies specific for rsv f-protein

Publications (1)

Publication Number Publication Date
ATE431159T1 true ATE431159T1 (de) 2009-05-15

Family

ID=23939500

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96919365T ATE431159T1 (de) 1995-06-07 1996-06-06 Für rsv f-proteine spezifische, menschliche, monoklonale antikörper mit hoher affinität

Country Status (22)

Country Link
US (11) US5811524A (de)
EP (2) EP2095827A1 (de)
JP (1) JP3771267B2 (de)
KR (1) KR100490687B1 (de)
CN (2) CN1680447A (de)
AR (1) AR003423A1 (de)
AT (1) ATE431159T1 (de)
AU (1) AU717061B2 (de)
BR (1) BR9608884A (de)
CA (1) CA2223033A1 (de)
CO (1) CO4480110A1 (de)
DE (1) DE69637930D1 (de)
IL (1) IL122404A0 (de)
MX (2) MXPA01011457A (de)
MY (1) MY137299A (de)
NO (1) NO324047B1 (de)
NZ (2) NZ310847A (de)
RS (1) RS50157B (de)
SA (1) SA96170384B1 (de)
UY (1) UY24255A1 (de)
WO (1) WO1996040252A1 (de)
ZA (1) ZA964434B (de)

Families Citing this family (202)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
FR2758331B1 (fr) * 1997-01-14 1999-03-05 Univ Bourgogne Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux
US7033589B1 (en) * 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
WO1999012553A1 (en) * 1997-09-08 1999-03-18 Idec Pharmaceuticals Corporation Methods for producing human antibodies in scid mice using dendritic cells
JP4334141B2 (ja) * 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6900299B1 (en) * 1999-03-11 2005-05-31 University Of South Florida Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection
CO5280147A1 (es) * 1999-05-18 2003-05-30 Smithkline Beecham Corp Anticuerpo humano monoclonal
GB9918788D0 (en) * 1999-08-10 1999-10-13 Leuven K U Res & Dev Antithrombotic effect of platelet glycoprotein 1b blocking monoclonal Fab fragments
US6680209B1 (en) * 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
AU2002219944B2 (en) * 2000-11-28 2008-02-21 Medimmune, Llc Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1255560B1 (de) 2000-02-02 2008-10-29 UNITED STATES GOVERNMENT as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE Cd40-ligand als adjuvant für respiratorisches syncytialvirus-impfstoff
JP2003525061A (ja) * 2000-03-01 2003-08-26 メディミューン,インコーポレイテッド 高効力組換え抗体およびその産生法
JP2003531866A (ja) * 2000-05-03 2003-10-28 メディミューン,インコーポレイテッド 抗体を用いた呼吸器疾患の組合せ治療法
US6855493B2 (en) * 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
EP1355919B1 (de) * 2000-12-12 2010-11-24 MedImmune, LLC Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20040096451A1 (en) * 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
WO2002060484A1 (en) 2001-01-31 2002-08-08 Idec Pharmaceuticals Corporation Use of cd23 antagonists for the treatment of neoplastic disorders
WO2002076507A2 (en) * 2001-03-23 2002-10-03 Genentech, Inc. Uses of opg ligand to modulate immune responses
EP1383800A4 (de) * 2001-04-02 2004-09-22 Idec Pharma Corp ZUSAMMEN MIT GnTIII EXPRIMIERTE REKOMBINANTE ANTIKÖRPER
WO2002102303A2 (en) * 2001-05-01 2002-12-27 Medimmune, Inc. Crystals and structure of synagis fab
JP4435563B2 (ja) * 2001-07-10 2010-03-17 バイオジェン アイデック インク アポトーシスプロセスの阻害および細胞性能の改善
EP1423510A4 (de) 2001-08-03 2005-06-01 Glycart Biotechnology Ag Antikörperglykosylierungsvarianten mit erhöhter antikörperabhängiger zellulärer zytotoxizität
US7306919B1 (en) * 2001-10-31 2007-12-11 Thornthwaite Jerry T Antigen-antibody cancer recognition system
WO2003063767A2 (en) * 2001-11-02 2003-08-07 Centocor Rsv proteins, antibodies, compositions, methods and uses
JP2005517401A (ja) * 2002-02-11 2005-06-16 アレクシオン ファーマシューティカルズ, インコーポレイテッド 免疫欠損非ヒト哺乳動物宿主におけるヒト抗体の産生
CA2482333A1 (en) * 2002-02-11 2003-08-21 Alexion Pharmaceuticals, Inc. Human antibodies for therapy against vaccinia or smallpox
CA2480419A1 (en) * 2002-03-28 2003-10-09 Yamanouchi Pharmaceutical Co., Ltd. Antiopoietin-related growth factor
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
AU2003243443B2 (en) * 2002-06-21 2008-11-06 Centocor, Inc. Method for generating monoclonal antibodies
KR100604038B1 (ko) * 2002-08-02 2006-07-24 주식회사유한양행 항체 중쇄 발현벡터
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
RS20050577A (sr) * 2003-01-27 2007-09-21 Biogen Idec Ma Inc., PREPARATI I POSTUPCI ZA TRETIRANjE KANCERA KORIŠĆENjEM IGSF9 I LIV-1
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
PL1606409T3 (pl) 2003-03-19 2011-02-28 Biogen Ma Inc Białko wiążące receptor Nogo
US20060257972A1 (en) * 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7070786B2 (en) * 2003-06-06 2006-07-04 Centocor, Inc. RSV proteins, antibodies, compositions, methods and uses
MXPA05014155A (es) 2003-06-27 2006-05-25 Abgenix Inc Anticuerpos dirigidos a los mutantes de delecion de receptor de factor de crecimiento epidermico y sus usos.
US20050239700A1 (en) * 2003-10-14 2005-10-27 Biogen Idec Inc. Treatment of cancer using antibodies to LRRC15
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US20060246079A1 (en) 2003-11-14 2006-11-02 Morrow Phillip R Neutralizing human antibodies to anthrax toxin
WO2005056052A1 (en) 2003-11-14 2005-06-23 Avanir Pharmaceuticals Neutralizing human antibodies to anthrax toxin generated by recall technology
WO2005081749A2 (en) * 2004-01-23 2005-09-09 Avanir Pharmaceuticals, Inc. Neutralizing human antibodies to anthraxtoxin
CN1914226B (zh) * 2003-11-25 2012-02-01 达纳-法伯癌症研究院有限公司 SARS-CoV抗体及其使用方法
WO2005092926A2 (en) 2004-03-19 2005-10-06 Amgen Inc. Reducing the risk of human and anti-human antibodies through v gene manipulation
PT1776136E (pt) 2004-06-24 2012-12-05 Biogen Idec Inc Tratamento de estados que envolvem desmielinização
EP1789070B1 (de) 2004-08-03 2012-10-24 Biogen Idec MA Inc. Taj in der neuronalen funktion
US20060063187A1 (en) * 2004-09-15 2006-03-23 Hotamisligil Gokhan S Modulation of XBP-1 activity for treatment of metabolic disorders
WO2006041970A2 (en) * 2004-10-08 2006-04-20 Abbott Biotechnology Ltd. Treatment of respiratory syncytial virus (rsv) infection
CA2585891A1 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
CA2593212A1 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Cripto binding molecules
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
ES2547463T3 (es) * 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
SI1904104T1 (sl) 2005-07-08 2013-12-31 Biogen Idec Ma Inc. Protitelesa SP35 in njihova uporaba
WO2008048230A2 (en) * 2005-08-15 2008-04-24 Emory University Methods of identifying biological targets and instrumentation to identify biological targets
EP1959979A4 (de) 2005-11-04 2010-01-27 Biogen Idec Inc Verfahren zur förderung des axonen-wachstums und des überlebens dopaminergischer neuronen
WO2007062037A2 (en) * 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
US20090175872A1 (en) 2005-12-02 2009-07-09 Biogen Idec Ma Inc. Treatment of Conditions Involving Demyelination
NZ600075A (en) * 2005-12-09 2013-12-20 Amc Amsterdam Means and methods for influencing the stability of antibody producing cells
ES2367322T3 (es) 2005-12-16 2011-11-02 Ribovax Biotechnologies Sa Métodos para obtener células inmortalizadas que secretan anticuerpos.
EP2526968A3 (de) 2006-01-27 2013-05-22 Biogen Idec MA Inc. Nogo-Rezeptorantagonisten
US20100040606A1 (en) * 2006-03-06 2010-02-18 Symphogen A/S Recombinant polyclonal antibody for treatment of respiratory syncytial virus infections
TW200813086A (en) 2006-05-11 2008-03-16 Hoffmann La Roche Immunereconstituted mouse
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
US20080171344A1 (en) * 2006-12-22 2008-07-17 Kapsner Kenneth P Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
GEP20125693B (en) 2007-01-09 2012-11-26 Biogen Idec Inc Sp35 antibodies and usage thereof
CA2678628A1 (en) * 2007-03-06 2008-09-12 Symphogen A/S Recombinant antibodies for treatment of respiratory syncytial virus infections
US7807168B2 (en) * 2007-04-10 2010-10-05 Vaccinex, Inc. Selection of human TNFα specific antibodies
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
BRPI0817257A2 (pt) * 2007-09-24 2015-06-16 Univ Vanderbilt Anticorpos moniclonais para vírus sincital respiratório e usos dos mesmos
WO2009062050A2 (en) 2007-11-08 2009-05-14 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
BRPI0819063A2 (pt) * 2007-11-27 2020-08-18 The University Of British Columbia método para tratamento de artrite, anticorpo, hibridoma, antagonista de 14-3-3, usos de um antagonista de 14-3-3, composições farmacêuticas, método para redução da expressão de mmp no sinóvio de um paciente e usos de uma composição farmacêutica
KR100938998B1 (ko) * 2008-01-08 2010-01-28 (주) 에이프로젠 호흡기 신시티움 바이러스에 대한 항체
US20090233295A1 (en) * 2008-01-29 2009-09-17 Elias Georges Trim59 directed diagnostics for neoplastic disease
LT2285408T (lt) 2008-06-05 2019-01-25 Ablynx N.V. Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui
EP2315779A2 (de) 2008-07-09 2011-05-04 Biogen Idec MA Inc. Antikörper gegen lingo oder fragmente davon enthaltende zusammensetzungen
EP2145621A1 (de) 2008-07-16 2010-01-20 Stephan Lück Verhinderung der Dehydrierung und Reduzierung der gluconeogenetischen Verluste von Aminosäuren durch Propan-1,2,3-Triol
JP5575377B2 (ja) * 2008-07-18 2014-08-20 シスメックス株式会社 抗rsウイルスモノクローナル抗体を用いたrsウイルス検出用キット及びイムノクロマトグラフィー用試験具、並びに新規な抗rsウイルスモノクローナル抗体
US8775090B2 (en) 2008-12-12 2014-07-08 Medimmune, Llc Crystals and structure of a human IgG Fc variant with enhanced FcRn binding
CN102341411A (zh) 2008-12-31 2012-02-01 比奥根艾迪克Ma公司 抗-淋巴细胞毒素抗体
WO2010111180A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
CN102459332B (zh) * 2009-06-05 2015-08-19 埃博灵克斯股份有限公司 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体
EP4183412B1 (de) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
MX2012001882A (es) 2009-08-13 2012-04-11 Crucell Holland Bv Anticuerpos contra el virus sincitial respiratorio (rsv) humano y metodos de uso.
EP2477658A2 (de) * 2009-09-16 2012-07-25 Duke University Hiv-1-antikörper
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
WO2011064382A1 (en) 2009-11-30 2011-06-03 Ablynx N.V. Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
SI2400298T1 (sl) * 2010-05-28 2013-11-29 F. Hoffmann-La Roche Ag Postopek kultivacije posamezne B-celice in izdelava specifičnih protiteles
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
EP2591000B1 (de) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Antikörper gegen humanes respiratorisches syncytialvirus (rsv) und ihre verwendung
EP2422618A1 (de) 2010-08-27 2012-02-29 Technologie Integrale Ltd. Tiermodell zur Beurteilung der Wirksamkeit eines HIV-Impfstoffs
US9956236B2 (en) 2011-02-07 2018-05-01 Cornell University Methods for increasing immune responses using agents that directly bind to and activate IRE-1
EP3699286A1 (de) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Dosierpläne und zusammensetzungen zur aav-vermittelten passiven immunisierung von luftbürtigen krankheitserregern
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
WO2013040307A1 (en) * 2011-09-16 2013-03-21 Granata, Francesco Methods of making cells, tissues, and antibodies
CN102850454B (zh) * 2011-09-27 2014-06-25 上海博沃生物科技有限公司 抗呼吸道合胞病毒的人单克隆抗体
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
AU2012340174A1 (en) 2011-11-16 2014-05-29 Amgen Inc. Methods of treating epidermal growth factor deletion mutant VIII related disorders
CN104159922B (zh) 2012-01-10 2018-03-02 比奥根Ma公司 对转运治疗性分子穿过血脑屏障的增强
US9796780B2 (en) 2012-05-14 2017-10-24 Biogen Ma Inc. LINGO-2 antagonists for treatment of conditions involving motor neurons
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
WO2014003137A1 (ja) * 2012-06-27 2014-01-03 旭化成メディカル株式会社 高アフィニティー抗体、及びその製造方法
BR112015009933A2 (pt) * 2012-11-13 2017-12-12 Genentech Inc métodos de obtenção de uma população de plasmablastos, de enriquecimento de plasmablastos e de identificação de plasmablasto
EP2948478B1 (de) 2013-01-25 2019-04-03 Amgen Inc. Antikörper gegen cdh19 für melanome
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
CN104994725B (zh) 2013-01-29 2022-07-01 巴斯夫植物科学有限公司 表达hcp6的抗真菌植物
CA2897482A1 (en) 2013-01-29 2014-08-07 Basf Plant Science Company Gmbh Fungal resistant plants expressing hcp7
WO2014118018A1 (en) 2013-01-29 2014-08-07 Basf Plant Science Company Gmbh Fungal resistant plants expressing ein2
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒f蛋白質的人類抗體及其使用方法
US9856313B2 (en) 2013-03-15 2018-01-02 Xiamen University Epitope of RSV fusion protein and antibody recognizing the same
UY35484A (es) 2013-03-15 2014-10-31 Amgen Res Munich Gmbh Molécula de unión de cadena simple que comprenden ABP de extremo N
US9505849B2 (en) 2013-03-15 2016-11-29 Amgen Research (Munich) Gmbh Antibody constructs for influenza M2 and CD3
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
DK3012633T3 (en) 2013-06-21 2018-08-13 Alfresa Pharma Corp Immunochromatography device for detection of RSV
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP3049521B1 (de) 2013-09-25 2019-03-06 Cornell University Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
JP6317440B2 (ja) 2013-10-29 2018-04-25 プレジデント アンド フェローズ オブ ハーバード カレッジ 酸化ストレスを阻害するための方法および組成物
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
CR20160519A (es) 2014-05-13 2017-01-27 The Trustees Of The Univ Of Pennysylvania Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos
ES2743809T3 (es) 2014-07-31 2020-02-20 Amgen Res Munich Gmbh Constructos de anticuerpo monocatenarios biespecificos específicos de especies cruzadas optimizados
ES2980787T3 (es) 2014-07-31 2024-10-03 Amgen Res Munich Gmbh Constructo de anticuerpo de cadena sencilla biespecífico con distribución tisular potenciada
AR101669A1 (es) 2014-07-31 2017-01-04 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
WO2016112270A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
BR112017016688B1 (pt) 2015-02-04 2024-01-23 Basf Plant Science Company Gmbh Método para aumentar a resistência fúngica, método para a produção de um produto e método para criar uma planta resistente a fungos
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
PL3283524T3 (pl) 2015-04-17 2023-06-12 Amgen Research (Munich) Gmbh Konstrukty biswoistego przeciwciała dla cdh3 i cd3
WO2016200543A2 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究(慕尼黑)公司 Cd70及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究(慕尼黑)公司 Msln及cd3抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究(慕尼黑)公司 Egfrviii及cd3抗體構築體
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究(慕尼黑)公司 Flt3及cd3抗體構築體
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究(慕尼黑)公司 Dll3及cd3抗體構築體
JO3555B1 (ar) 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
AR107582A1 (es) 2016-02-03 2018-05-16 Amgen Res Munich Gmbh Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
UA126657C2 (uk) 2016-02-03 2023-01-11 Емджен Рісерч (Мюнік) Ґмбг ОДНОЛАНЦЮГОВА КОНСТРУКЦІЯ АНТИТІЛА ДО BCMA І CD3<font face="Symbol">e</font>
US10626126B2 (en) * 2016-04-08 2020-04-21 Pulmocide Limited Compounds
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
EP3054014A3 (de) 2016-05-10 2016-11-23 BASF Plant Science Company GmbH Benutzung einer fungizids auf transgenen pflanzen
US11312761B2 (en) * 2016-10-21 2022-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
AU2017345786B2 (en) 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
WO2018075954A2 (en) 2016-10-21 2018-04-26 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
CR20190408A (es) 2017-02-02 2020-01-31 Amgen Inc Composición farmacéutica de bajo ph que comprende construcciones de anticuerpos que activan linfocitos t antecedentes
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
TW201837170A (zh) 2017-02-28 2018-10-16 賓州大學委員會 新穎aav媒介的流感疫苗
RS65241B1 (sr) 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
TWI911431B (zh) 2017-03-01 2026-01-11 英商梅迪繆思有限公司 抗rsv單株抗體配製物
MA48763A (fr) 2017-05-05 2020-04-08 Amgen Inc Composition pharmaceutique comprenant des constructions d'anticorps bispécifiques pour un stockage et une administration améliorés
EP3717632B1 (de) 2017-11-30 2022-10-26 F. Hoffmann-La Roche AG Verfahren zur kultivierung von b-zellen
AU2018383679C1 (en) 2017-12-11 2026-05-28 Amgen Inc. Continuous manufacturing process for bispecific antibody products
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對muc17和cd3之雙特異性抗體構建體
WO2020025532A1 (en) 2018-07-30 2020-02-06 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
BR112021002032A2 (pt) 2018-08-03 2021-07-20 Amgen Research (Munich) Gmbh construtos de anticorpos para cldn18.2 e cd3
PL3843757T3 (pl) 2018-08-27 2024-08-05 Affimed Gmbh Kriokonserwowane komórki nk wstępnie obciążone konstruktem przeciwciała
MX2021003976A (es) 2018-10-11 2021-05-27 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecificos.
EP3938504A1 (de) 2019-03-11 2022-01-19 Basf Se Amylasen und verfahren zur herstellung und verwendung davon
US20220259547A1 (en) 2019-06-13 2022-08-18 Amgeng Inc. Automated biomass-based perfusion control in the manufacturing of biologics
US20220306741A1 (en) 2019-09-10 2022-09-29 Amgen Inc. Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
WO2021097344A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
IL293640A (en) 2019-12-20 2022-08-01 Amgen Inc CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
CA3160927A1 (en) 2019-12-27 2021-07-01 Affimed Gmbh Method for the production of bispecific fcyriii x cd30 antibody construct
US20230093169A1 (en) 2020-01-22 2023-03-23 Amgen Research (Munch) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
CN115427454A (zh) 2020-03-19 2022-12-02 安进公司 针对粘蛋白17的抗体及其用途
WO2021202463A1 (en) 2020-03-30 2021-10-07 Danisco Us Inc Anti-rsv antibodies
WO2021236638A1 (en) 2020-05-19 2021-11-25 Amgen Inc. Mageb2 binding constructs
JP2023527972A (ja) 2020-05-29 2023-07-03 アムジエン・インコーポレーテツド Cd33及びcd3に結合する二重特異性コンストラクトの有害作用軽減投与
EP4225792A1 (de) 2020-10-08 2023-08-16 Affimed GmbH Trispezifische bindemittel
EP4240770A1 (de) 2020-11-06 2023-09-13 Amgen Research (Munich) GmbH Polypeptidkonstrukte mit selektiver bindung an cldn6 und cd3
AU2021373318A1 (en) 2020-11-06 2023-05-25 Amgen Inc. Antigen binding domain with reduced clipping rate
TW202225188A (zh) 2020-11-06 2022-07-01 德商安美基研究(慕尼黑)公司 與cd3結合的多肽構建體
CA3200317A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
AR124216A1 (es) 2020-12-01 2023-03-01 Univ Pennsylvania Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen
US20250282887A1 (en) 2021-04-02 2025-09-11 Amgen Inc. Mageb2 binding constructs
JP2024515788A (ja) 2021-04-27 2024-04-10 ジェネレーション バイオ カンパニー 治療抗体を発現する非ウイルスdnaベクター及びその使用
MX2023012931A (es) 2021-05-06 2023-11-13 Amgen Res Munich Gmbh Moleculas de union a antigeno dirigidas a cd20 y cd22 para su uso en enfermedades proliferativas.
JP2024529381A (ja) 2021-07-30 2024-08-06 アフィメド ゲーエムベーハー デュプレックスボディ
TW202334221A (zh) 2021-11-03 2023-09-01 德商安富美德有限公司 雙特異性cd16a結合劑
WO2023079493A1 (en) 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
EP4493212A1 (de) 2022-03-14 2025-01-22 Generation Bio Co. Heterologe prime-boost-impfstoffzusammensetzungen und verfahren zur verwendung
AU2023268600A1 (en) 2022-05-12 2024-11-07 Amgen Research (Munich) Gmbh Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
AU2023343470A1 (en) 2022-09-14 2025-02-06 Amgen Inc. Bispecific molecule stabilizing composition
MX2025014635A (es) 2023-06-14 2026-02-03 Amgen Inc Moleculas captadoras de enmascaramiento de celulas t
IL328264A (en) 2023-11-14 2026-07-01 Janssen Pharmaceuticals Inc Anti-Respiratory Syncytial Virus Antibodies and Their Uses
CN120248057B (zh) * 2024-12-26 2025-12-02 北京华诺泰生物医药科技有限公司 一种呼吸道合胞病毒f蛋白突变体及其应用
WO2026161391A2 (en) 2025-01-21 2026-07-30 Bristol-Myers Squibb Company Cd19 binding molecules including cd3- and cd19- bispecific t cell engagers and related methods and uses

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0043272B1 (de) * 1980-07-01 1984-06-13 National Research Development Corporation Herstellung von Virusantigenen
DE3235924T1 (de) * 1981-03-06 1983-05-05 Celltech Ltd., Slough, Berkshire Monoklonaler antikoerper
US5340926A (en) * 1983-03-25 1994-08-23 Celltech, Limited Process for the recovery of recombinantly produced protein from insoluble aggregate
US5332805A (en) * 1984-02-03 1994-07-26 Celltech Limited Process for the recovery of recombinantly produced chymosin from insoluble aggregate
FR2590674B1 (fr) * 1985-11-25 1989-03-03 Inst Nat Sante Rech Med Nouveaux reactifs de diagnostic
US5149650A (en) * 1986-01-14 1992-09-22 University Of North Carolina At Chapel Hill Vaccines for human respiratory virus
US4659563A (en) * 1986-01-27 1987-04-21 Miles Laboratories, Inc. High titer anti-respiratory syncytial virus intravenous immune globulin
US4717766A (en) * 1986-01-27 1988-01-05 Miles Laboratories, Inc. Method of preparing high titer anti-respiratory syncytial virus intravenous immune globulin
US5271927A (en) * 1986-02-13 1993-12-21 Celltech Limited Antibody conjugates with macrocyclic ligands
US5468606A (en) * 1989-09-18 1995-11-21 Biostar, Inc. Devices for detection of an analyte based upon light interference
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
GB8719041D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
WO1989005823A1 (en) * 1987-12-23 1989-06-29 The Upjohn Company Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
US5183657A (en) * 1988-03-11 1993-02-02 Celltech Limited Antibodies for use in antilymphocyte antibody therapy
US5137804A (en) * 1988-05-10 1992-08-11 E. I. Du Pont De Nemours And Company Assay device and immunoassay
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5354554A (en) * 1989-02-10 1994-10-11 Celltech Limited Crosslinked antibodies and processes for their preparation
US6093872A (en) * 1989-05-05 2000-07-25 Systemix, Inc. Extended human hematopoiesis in a heterologous host
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
US5518725A (en) * 1989-09-25 1996-05-21 University Of Utah Research Foundation Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
US5279935A (en) * 1990-03-01 1994-01-18 Becton, Dickinson And Company Method of immunossay including deactivation of endogenous alkaline phosphatase
JPH04507109A (ja) * 1990-05-03 1992-12-10 システミックス インコーポレイテッド 免疫無防備状態宿主中におけるヒトリンパ球組織
EP0581882B1 (de) * 1991-04-22 1998-01-07 Massachusetts Health Research Institute, Inc. (Mhri) Verfahren für das screening von plasma-proben für einen effektiven antikörpernachweis gegen respiratorische viren
JPH06507404A (ja) * 1991-05-01 1994-08-25 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 感染性の呼吸性疾患の治療方法
CA2044940A1 (en) * 1991-06-10 1992-12-11 Inder M. Verma Transdominant negative proto-oncogene
WO1993005796A1 (en) * 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
US5240694A (en) * 1991-09-23 1993-08-31 University Of Virginia Combined antiviral and antimediator treatment of common colds
US5418136A (en) * 1991-10-01 1995-05-23 Biostar, Inc. Devices for detection of an analyte based upon light interference
AU3923293A (en) * 1992-03-20 1993-10-21 Immunet Human monoclonal antibodies and methods for human monoclonal antibody production
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
AU686113B2 (en) * 1992-09-16 1998-02-05 Scripps Research Institute, The Human neutralizing monoclonal antibodies to respiratory syncytial virus
EP0680337A4 (de) * 1993-01-12 1997-07-30 Anthony George Gristina Methoden und zusammensetzungen zur direkter konzentrierter verabreichung passiver immunität.
US5424189A (en) * 1993-03-05 1995-06-13 Kansas State University Research Foundation Bovine respiratory syncytial virus detection and primers
NZ269735A (en) * 1993-07-30 1998-01-26 Oravax Inc Monoclonal iga antibody against respiratory syncytial virus (rsv)
US5506209A (en) * 1994-05-26 1996-04-09 Abbott Laboratories Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5538952A (en) * 1994-05-26 1996-07-23 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
US5538733A (en) * 1994-07-07 1996-07-23 Willmar Poultry Company, Inc. Method of priming an immune response in a one-day old animal
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof

Also Published As

Publication number Publication date
KR19990022645A (ko) 1999-03-25
US5958765A (en) 1999-09-28
CN1680447A (zh) 2005-10-12
AR003423A1 (es) 1998-08-05
WO1996040252A1 (en) 1996-12-19
NZ310847A (en) 1999-05-28
US5939068A (en) 1999-08-17
US20070082002A1 (en) 2007-04-12
NO324047B1 (no) 2007-08-06
EP0854730B1 (de) 2009-05-13
US5955364A (en) 1999-09-21
ZA964434B (en) 1996-12-10
US5866125A (en) 1999-02-02
JP3771267B2 (ja) 2006-04-26
NO975621L (no) 1998-02-04
CN1192695A (zh) 1998-09-09
MY137299A (en) 2009-01-30
KR100490687B1 (ko) 2005-08-05
NZ335241A (en) 1999-07-29
EP2095827A1 (de) 2009-09-02
MXPA01011457A (es) 2005-09-08
CN1198648C (zh) 2005-04-27
YU36096A (sh) 1999-06-15
UY24255A1 (es) 1996-06-18
US20040005323A1 (en) 2004-01-08
US20040076631A1 (en) 2004-04-22
US20020081723A1 (en) 2002-06-27
US6537809B2 (en) 2003-03-25
AU6172096A (en) 1996-12-30
AU717061B2 (en) 2000-03-16
IL122404A0 (en) 1998-06-15
JPH11507640A (ja) 1999-07-06
EP0854730A1 (de) 1998-07-29
HK1015282A1 (en) 1999-10-15
US5840298A (en) 1998-11-24
US5811524A (en) 1998-09-22
DE69637930D1 (de) 2009-06-25
EP0854730A4 (de) 2002-11-06
RS50157B (sr) 2009-05-06
SA96170384B1 (ar) 2006-07-31
CO4480110A1 (es) 1997-07-09
US20020001798A1 (en) 2002-01-03
CA2223033A1 (en) 1996-12-19
BR9608884A (pt) 1999-07-06
NO975621D0 (no) 1997-12-04
MX9709778A (es) 1998-07-31
US6413771B1 (en) 2002-07-02

Similar Documents

Publication Publication Date Title
DE69637930D1 (de) Für rsv f-proteine spezifische, menschliche, monoklonale antikörper mit hoher affinität
FI964845A7 (fi) CD44v6:n vastaiset monoklonaaliset vasta-aineet
DK1516629T3 (da) Humaniseret anti-CD-11a antibodies
DE69628178D1 (de) Messumformer für prozessteurung
PT719859E (pt) Anticorpo monoclonal anti-alfa v-integrina
CY2007012I1 (el) Αντισωματα anti-vegf
FI900332A7 (fi) Ilmentämisjärjestelmä kimeeristen monoklonaalisten vasta-aineiden tuottamiseksi
FI973543A0 (fi) Menetelmä heteromultimeeristen polypeptidien valmistamiseksi
TR199600357A2 (tr) Rekombinant simanlik (Ob) proteinleri.
LV11630A (lv) T sunu antigena receptora V apgabala pilna garuma olbaltumvielas
DE69828154D1 (de) Anti-alphavbeta3 humanizierte monoklonale antikörper
NO980566D0 (no) Allergen-XCD32 fusjonsproteiner
ATE285474T1 (de) Haemophilus adhäsionsproteinen
DE69623589D1 (de) Heizsystem für fahrzeuge
DE69604905D1 (de) System für abtastlithographie mit gegenbewegung
BR9509902A (pt) Fragmentos de anticorpos monoclonais apresentando atividade imunosupressante
FI945877L (fi) Menetelmä proteiini C:n tuottamiseksi
EP0832126A4 (de) G-protein rezeptor htnad29
DE3886545D1 (de) Monoklonale human-antikörper, spezifisch für rh(d).
IT8821702A0 (it) Nuovo anticorpo monoclonale.
NO985281D0 (no) Monoklonalt antihumant MP52-antistoff
DK0919617T3 (da) Monoklonale antistoffer mod humant MP52
SI0742795T1 (en) Immuno-stimulatory monoclonal antibodies
BR1100555B1 (pt) anticorpos monoclonais humanizados.
NO973515D0 (no) Anti-fedme proteiner

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties